The Myeloma Beacon just ran an article titled:
Revlimid May Be More Effective Than Thalidomide In Newly Diagnosed Multiple Myeloma
Really? You think? Don’t get me wrong, thalidomide (Thalomid), still has it’s place in treating refractory multiple myeloma. In many patients, Thalomid and dex works after Revlimid stops working. But that’s it. Let’s get Revlimid approved immediately for first line use in newly diagnosed myeloma patients, so docs don’t have to use it “off label” in order to treat them. Thalomid has more side-effects than Revlimid and, as the article title so proudly proclaims, Revlimid may be more effective.
I’m wearing my patient hat here, but articles like this infuriate me! Let’s move forward! I know, I know—the FDA, and researchers, need to follow protocol. There is a process. I get it! Doesn’t mean I have to like it! Bet you readers didn’t know I could get so emotional—and no, it isn’t a “dex day” for me!
Feel good and keep smiling! Pat